BEP—Γ–@
€–Ϊ–Ό Šξ€—Κ ’PˆΚ }ަ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 @ @ @ @ @ @ @
‘S‘ΜƒXƒPƒWƒ…[ƒ‹ œ -- -- -- -- ‹x ‹x ‹x -- ‹x ‹x ‹x ‹x ‹x ‹x -- ‹x ‹x ‹x ‹x ‹x @ @ @ @ @ @ @
ƒ‰ƒ“ƒ_(CDDP) 20 mg/‡u š š š š š @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
ƒGƒgƒ|ƒVƒh(VP-16) 100 mg/‡u š š š š š @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
ƒuƒŒƒI(BLM) 30 mg @ š @ @ @ @ @ @ š @ @ @ @ @ @ š @ @ @ @ @ @ @ @ @ @ @ @
@ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
@ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @
y’ˆΣƒ`ƒ…ƒEƒCŽ–€ƒWƒRƒEz
“K—pƒeƒLƒˆƒE‚Ν—‘‘ƒŽξᇃ‰ƒ“ƒ\ƒEƒVƒ…ƒˆƒE‚Μ“ΰƒEƒ`AγσΧ–EŽξᇃnƒCƒTƒCƒ{ƒEƒVƒ…ƒˆƒE‚ΙŒΐƒJƒM‚ι